AR127176A1 - Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos - Google Patents

Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos

Info

Publication number
AR127176A1
AR127176A1 ARP220102616A ARP220102616A AR127176A1 AR 127176 A1 AR127176 A1 AR 127176A1 AR P220102616 A ARP220102616 A AR P220102616A AR P220102616 A ARP220102616 A AR P220102616A AR 127176 A1 AR127176 A1 AR 127176A1
Authority
AR
Argentina
Prior art keywords
antigen
polypeptides
binding
chain variable
variable region
Prior art date
Application number
ARP220102616A
Other languages
English (en)
Spanish (es)
Inventor
Ronnie Rong Wei
Ling Xu
Zhi Yang
- Nabel Gary J Yong
Original Assignee
Modex Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutics filed Critical Modex Therapeutics
Publication of AR127176A1 publication Critical patent/AR127176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP220102616A 2021-09-29 2022-09-28 Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos AR127176A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29

Publications (1)

Publication Number Publication Date
AR127176A1 true AR127176A1 (es) 2023-12-27

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102616A AR127176A1 (es) 2021-09-29 2022-09-28 Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos

Country Status (13)

Country Link
US (1) US20250197481A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408892A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537827A (cg-RX-API-DMAC7.html)
KR (1) KR20240099226A9 (cg-RX-API-DMAC7.html)
CN (1) CN118660907A (cg-RX-API-DMAC7.html)
AR (1) AR127176A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022357501A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232365A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000890A1 (cg-RX-API-DMAC7.html)
IL (1) IL311762A (cg-RX-API-DMAC7.html)
MX (1) MX2024003804A (cg-RX-API-DMAC7.html)
TW (1) TW202325744A (cg-RX-API-DMAC7.html)
WO (1) WO2023056315A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6407726B2 (ja) * 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Also Published As

Publication number Publication date
WO2023056315A1 (en) 2023-04-06
CN118660907A (zh) 2024-09-17
EP4408892A4 (en) 2025-11-19
US20250197481A1 (en) 2025-06-19
EP4408892A1 (en) 2024-08-07
JP2024537827A (ja) 2024-10-16
KR20240099226A9 (ko) 2025-12-10
MX2024003804A (es) 2024-06-11
CL2024000890A1 (es) 2024-10-11
TW202325744A (zh) 2023-07-01
IL311762A (en) 2024-05-01
CA3232365A1 (en) 2023-04-06
KR20240099226A (ko) 2024-06-28
AU2022357501A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AR076797A1 (es) Anticuerpos triespecificos o tetraespecificos
PE20221021A1 (es) Proteinas de union a antigeno que se unen especificamente a mage-a
CL2024000907A1 (es) Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos
PE20231851A1 (es) Proteinas que se unen a nkg2d, cd16 y clec12a
PE20190514A1 (es) Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123
AR077088A1 (es) Proteinas biespecificas de union a antigeno
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
CL2024000890A1 (es) Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos en el vih
JP2018537415A5 (cg-RX-API-DMAC7.html)
RU2016138347A (ru) Трифункциональная антигенсвязывающая молекула
CO2023009615A2 (es) Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31
JP2016536322A5 (cg-RX-API-DMAC7.html)
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
CL2021000942A1 (es) Anticuerpos anti-npr1 y usos relacionados.
ES2713428T3 (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y métodos de producción y uso de los mismos
PE20240761A1 (es) Proteinas de union a psma y usos de estas
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
MX2023012489A (es) Polipeptido de fusion biespecifico multifuncional.
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
MX2022009138A (es) Anticuerpos y fragmentos de anticuerpos anti-her2 condicionalmente activos, sus inmunoconjugados y usos de estos.
AR122286A1 (es) Anticuerpos potenciadores del factor h y usos de estos
AR125210A1 (es) Anticuerpos dirigidos a cd22 y cd79b
AR127177A1 (es) Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos
AR125980A1 (es) Anticuerpos específicamente unidos a la proteína asm
AR124609A1 (es) Anticuerpos divididos y métodos de uso